Meeting
2022 ASCO Annual Meeting
Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
Authors
Federico Cappuzzo
Istituto Nazionale Tumori Regina Elena, Roma, Italy
Federico Cappuzzo , Giulia Pasello , Angelo Delmonte , Lorenza Landi , Beatrice Benetti , Giulio Metro , Mario Rosario D'Andrea , Stefania Gori , Gloria Borra , Francesca Mazzoni , Claudio Verusio , Maria Pagano , Diana Giannarelli , Andrea Vincent Bonetti , Michele Maio , Antonino Scimone , Vincenzo Adamo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04884282
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9140)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9140
Abstract #
TPS9140
Poster Bd #
124b
Abstract Disclosures
Similar Posters
First Author: Michael Masetti
Poster
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
First Author: Prantesh Jain
Poster
2021 ASCO Annual Meeting
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
First Author: Hidetoshi Hayashi
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva